AIM OF THE STUDY: The aim of this study is to evaluate the efficacy and safety of levetiracetam (LEV) as first-line treatment of neonatal seizures. MATERIALS AND METHODS: This study was conducted in patients of Neonatal Intensive Care Unit of Santo Bambino Hospital, University of Catania, Italy, from January to August 2016. A total of 16 neonates with convulsions not associated with major syndromes, which required anticonvulsant therapy, were included and underwent IV LEV at standard doses. RESULTS: All patients responded to treatment, with a variety range of seizure resolution period (from 24 h to 15 days; mean hours: 96 ± 110.95). No patient required a second anticonvulsant therapy. Regarding safety of LEV, no major side-effects were observed. CONCLUSIONS: To our knowledge, it is one of the few studies confirming the efficiency of LEV as first-line treatment in seizures of this age group. LEV was effective in resolving seizures and was safely administered in the current study.

Falsaperla R, V.G. (2017). Levetiracetam in Neonatal Seizures as First-line Treatment: A Prospective Study. JOURNAL OF PEDIATRIC NEUROSCIENCES, 12(1), 24-28 [10.4103/jpn.JPN_172_16].

Levetiracetam in Neonatal Seizures as First-line Treatment: A Prospective Study

Falsaperla R;Corsello G
2017-01-01

Abstract

AIM OF THE STUDY: The aim of this study is to evaluate the efficacy and safety of levetiracetam (LEV) as first-line treatment of neonatal seizures. MATERIALS AND METHODS: This study was conducted in patients of Neonatal Intensive Care Unit of Santo Bambino Hospital, University of Catania, Italy, from January to August 2016. A total of 16 neonates with convulsions not associated with major syndromes, which required anticonvulsant therapy, were included and underwent IV LEV at standard doses. RESULTS: All patients responded to treatment, with a variety range of seizure resolution period (from 24 h to 15 days; mean hours: 96 ± 110.95). No patient required a second anticonvulsant therapy. Regarding safety of LEV, no major side-effects were observed. CONCLUSIONS: To our knowledge, it is one of the few studies confirming the efficiency of LEV as first-line treatment in seizures of this age group. LEV was effective in resolving seizures and was safely administered in the current study.
2017
Falsaperla R, V.G. (2017). Levetiracetam in Neonatal Seizures as First-line Treatment: A Prospective Study. JOURNAL OF PEDIATRIC NEUROSCIENCES, 12(1), 24-28 [10.4103/jpn.JPN_172_16].
File in questo prodotto:
File Dimensione Formato  
Falsaperla_J Pediatr Neurosci 2017.pdf

Solo gestori archvio

Tipologia: Post-print
Dimensione 281.1 kB
Formato Adobe PDF
281.1 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/416414
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 28
social impact